Immuron Limited (IMRN): Price and Financial Metrics


Immuron Limited (IMRN): $2.47

-0.02 (-0.88%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

IMRN Stock Price Chart Interactive Chart >

Price chart for IMRN

IMRN Price/Volume Stats

Current price $2.47 52-week high $5.20
Prev. close $2.49 52-week low $2.32
Day low $2.46 Volume 1,900
Day high $2.55 Avg. volume 493,280
50-day MA $2.81 Dividend yield N/A
200-day MA $0.00 Market Cap 14.07M

Immuron Limited (IMRN) Company Bio


Immuron Limited focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company was founded in 1994 and is based in Australia.


IMRN Latest News Stream


Event/Time News Detail
Loading, please wait...

IMRN Latest Social Stream


Loading social stream, please wait...

View Full IMRN Social Stream

Latest IMRN News From Around the Web

Below are the latest news stories about Immuron Ltd that investors may wish to consider to help them evaluate IMRN as an investment opportunity.

Immuron gains on tax concession cash refund from Australian Government (NASDAQ:IMRN)

Immuron <> ADRs have approached the highest level in more than three months after announcing a cash refund of approximately AUD 306K from the Australian government.The refund was…

Seeking Alpha | January 18, 2022

Immuron Receives AUD $306,154 R&D Tax Concession Refund

MELBOURNE, Australia, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $306,154 for eligible research and development expenditure inc

Yahoo | January 17, 2022

Immuron secures European Patent on drug composition for travelers diarrhea

Immuron (IMRN) has been granted a European Patent for compositions and methods for treating travelers diarrhea

Seeking Alpha | January 13, 2022

Immuron Receives European Patent on Drug Composition to Treat Travelers’ Diarrhea

MELBOURNE, Australia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that it has been granted a European Patent for compositions and methods for treating travelers’ diarrhea. European Patent 3159357, entitled “Composition and method for the treatment and prevention of enteric bacte

Yahoo | January 13, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, trader!

William White on InvestorPlace | January 12, 2022

Read More 'IMRN' Stories Here

IMRN Price Returns

1-mo N/A
3-mo -26.49%
6-mo -1.20%
1-year N/A
3-year -22.57%
5-year -71.28%
YTD -1.20%
2021 -60.75%
2020 75.48%
2019 N/A
2018 0.00%
2017 N/A

Continue Researching IMRN

Want to see what other sources are saying about Immuron Ltd's financials and stock price? Try the links below:

Immuron Ltd (IMRN) Stock Price | Nasdaq
Immuron Ltd (IMRN) Stock Quote, History and News - Yahoo Finance
Immuron Ltd (IMRN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4912 seconds.